- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05536167
Prospective Multicenter Study to Characterize the REAL-WORLD EVIDENCE Regarding Safety and Performance of the Aspiration Catheters Family
January 31, 2024 updated by: Arthesys
The purpose of this post market study is to collect clinical data of the Arthesys Aspiration catheters family during percutaneous intervention and/or stenting procedure of vessels in the central and peripheral circulation system, including saphenous vein grafts, to support MDR submission.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
57
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Laure Morsiani
- Phone Number: 0176739236
- Email: lmorsiani@cerc-europe.org
Study Locations
-
-
-
La Rochelle, France
- Hôpital Saint Louis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients undergoing PTA/PTCA and/or stenting procedures and presenting thrombus in the central and peripheral circulatory system, including saphenous vein grafts.
Description
Inclusion Criteria:
Patients will be included as per Instructions for Use (IFU), Hospital standard of care and Good Clinical Practice (GCP):
- Patient with a percutaneous intervention to a native coronary, saphenous vein graft, or peripheral arteries;
- Patient with angiographic evidence of thrombus;
- Patient > or = 50 kg;
- Patient >18 years;
- Patient who understands the trial requirements and the treatment procedures and provides written informed consent.
Exclusion Criteria:
- Patients will be excluded as per IFU, Hospital standard of care and GCP, also if there are under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy endpoint
Time Frame: up to end of procedure
|
successful debris aspiration (macroscopic observation of the retrieved material in the filter) during the procedure.
|
up to end of procedure
|
Safety endpoint
Time Frame: up to end of procedure
|
insertion and retrieval of the catheter up to the treated vessel without complication.
|
up to end of procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Performance - TIMI flow grade
Time Frame: up to end of procedure
|
Final Thrombolysis In Myocardial Infarction (TIMI) Flow Grade at procedure
|
up to end of procedure
|
Safety - absence of complications
Time Frame: up to end of procedure
|
Absence of complications during hospitalization (per standard hospital of care): cardiovascular death, recurrent myocardial infarction, cardiogenic shock, worsening of TIMI flow due to aspiration catheter, new or worsening New York Heart Association (NYHA) Class IV heart failure,
|
up to end of procedure
|
Performance - TIMI thrombus grade
Time Frame: up to end of procedure
|
Final TIMI Thrombus Grade at procedure
|
up to end of procedure
|
Performance
Time Frame: up to end of procedure
|
Distal Embolization Rate at procedure
|
up to end of procedure
|
Safety - absence of Serious Adverse Event
Time Frame: up to end of procedure
|
Incident of Device Related SAEs during aspiration catheter use
|
up to end of procedure
|
Safety - absence of stroke
Time Frame: up to end of procedure
|
Stroke during aspiration catheter use (per hospital standard of care).
|
up to end of procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 12, 2022
Primary Completion (Actual)
December 31, 2023
Study Completion (Actual)
December 31, 2023
Study Registration Dates
First Submitted
September 7, 2022
First Submitted That Met QC Criteria
September 7, 2022
First Posted (Actual)
September 10, 2022
Study Record Updates
Last Update Posted (Estimated)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 31, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ART-ASPI CATHETER-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
-
Bionorica Research GmbHCompletedCentral Neuropathic Pain in Multiple SclerosisGermany
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingEvaluation of the Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in Patients With Amyotrophic Lateral Sclerosis
-
University of AarhusCompletedHeart Failure | Stroke | Epilepsy | Pain | Multiple Sclerosis | Hypertension | Diabetes Mellitus | Cancer | Chronic Kidney Diseases | Schizophrenia | Parkinson Disease | Migraine | Inflammatory Bowel Diseases | Anemia | HIV/AIDS | Atrial Fibrillation | Dyslipidemias | Allergy | Osteoporosis | Ischemic Heart Disease | Hearing Disorders | Substance... and other conditions
-
Centre Hospitalier Universitaire de LiegeSanofi; Takeda; University of Liege; Orchard Therapeutics; Centre Hospitalier Régional... and other collaboratorsRecruitingCongenital Adrenal Hyperplasia | Hemophilia A | Hemophilia B | Mucopolysaccharidosis I | Mucopolysaccharidosis II | Cystic Fibrosis | Alpha 1-Antitrypsin Deficiency | Sickle Cell Disease | Fanconi Anemia | Chronic Granulomatous Disease | Wilson Disease | Severe Congenital Neutropenia | Ornithine Transcarbamylase... and other conditionsBelgium